A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

A Phase 2 Diagnostic Imaging Study With 99mTc-MIP-1404 in Men With High-Risk Prostate Cancer Scheduled for Radical Prostatectomy (RP) and Extended Pelvic Lymph Node Dissection (EPLND) Compared to Histopathology

Sponsors and Collaborators
Molecular Insight Pharmaceuticals, Inc.

Contact
Robert Crummet
617-871-6715
rcrummet@molecularinsight.com

Brooke Hegarty, MSHS
617-871-6654
bhegarty@molecularinsight.com

Principal Investigator
Douglas Scherr, M.D., New York Presbyterian Hospital - Cornell

ClinicalTrials.gov Identifier
NCT01667536

Loading links....
You must be a registered member of Renal and Urology News to post a comment.

Sign Up for Free e-newsletters